Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Not Models, but Compute Power: SpaceX Is Building a New Pillar of the AI Economy
SpaceX shares under debt pressure
US Open: Wall Street Buys Into Peace Hopes
🚩 Booz Allen Hamilton Stock: The Biggest Loser in the U.S. Defense Sector?